OpenURL Connection Search

Select item for more details and to access through your institution.

NCX1 disturbs calcium homeostasis and promotes RANKL-induced osteoclast differentiation by regulating JNK/c-Fos/NFATc1 signaling pathway in multiple myeloma.
Published in:
Clinical & Experimental Medicine, 2023, v. 23, n. 5, p. 1581, doi. 10.1007/s10238-022-00905-1
By:
- Li, Tingting;
- Qiu, Dongbiao;
- Chen, Qingjiao;
- Yang, Apeng;
- Chen, Junmin;
- Zeng, Zhiyong
Publication type:
Article
CXCR4-Directed PET/CT with [68Ga]Pentixafor in Central Nervous System Lymphoma: A Comparison with [18F]FDG PET/CT.
Published in:
Molecular Imaging & Biology, 2022, v. 24, n. 3, p. 416, doi. 10.1007/s11307-021-01664-3
By:
- Chen, Zhenying;
- Yang, Apeng;
- Zhang, Jiaying;
- Chen, Aihong;
- Zhang, Yuanqing;
- Huang, Chao;
- Chen, Shaoming;
- Yao, Shaobo;
- Miao, Weibing
Publication type:
Article
Single cell RNA-seq data and bulk gene profiles reveal a novel signature of disease progression in multiple myeloma.
Published in:
Cancer Cell International, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12935-021-02190-6
By:
- Zeng, Zhiyong;
- Lin, Junfang;
- Zhang, Kejie;
- Guo, Xizhe;
- Zheng, Xiaoqiang;
- Yang, Apeng;
- Chen, Junmin
Publication type:
Article
Allo-HSCT recipients with invasive fungal disease and ongoing immunosuppression have a high risk for developing tuberculosis.
Published in:
Scientific Reports, 2019, v. 9, n. 1, p. 1, doi. 10.1038/s41598-019-56013-w
By:
- Yang, Apeng;
- Shi, Jimin;
- Luo, Yi;
- Ye, Yishan;
- Tan, Yamin;
- Huang, He;
- Zhao, Yanmin
Publication type:
Article
Akt2 mediates glucocorticoid resistance in lymphoid malignancies through FoxO3a/Bim axis and serves as a direct target for resistance reversal.
Published in:
Cell Death & Disease, 2018, v. 9, n. 10, p. 1, doi. 10.1038/s41419-018-1043-6
By:
- Xie, Mixue;
- Yang, Apeng;
- Ma, Jiexian;
- Wu, Min;
- Xu, Hongyue;
- Wu, Kefei;
- Jin, Youxin;
- Xie, Yanhui
Publication type:
Article
SSBP1 is a novel prognostic marker and promotes disease progression via p38MAPK signaling pathway in multiple myeloma.
Published in:
Molecular Carcinogenesis, 2024, v. 63, n. 4, p. 728, doi. 10.1002/mc.23684
By:
- Xiao, Pingping;
- Wang, Jizhen;
- Li, Tingting;
- Yang, Apeng;
- Qiu, Dongbiao;
- Chen, Junmin;
- Zeng, Zhiyong
Publication type:
Article
Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study.
Published in:
Signal Transduction & Targeted Therapy, 2024, v. 9, n. 1, p. 1, doi. 10.1038/s41392-024-01941-x
By:
- Zeng, Zhiyong;
- Yang, Apeng;
- Yang, Jingke;
- Zhang, Sheng;
- Xing, Zhen;
- Wang, Xingfu;
- Mei, Wenzhong;
- Jiang, Changzhen;
- Lin, Junfang;
- Wu, Xiyue;
- Xue, Yihui;
- Wu, Zanyi;
- Yu, Lianghong;
- Wang, Dengliang;
- Chen, Jianwu;
- Zheng, Shufa;
- Lin, Qiaoxian;
- Chen, Qingjiao;
- Dong, Jinfeng;
- Zheng, Xiaoqiang
Publication type:
Article
[68Ga]Pentixafor PET/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [18F]FDG PET/CT.
Published in:
European Journal of Nuclear Medicine & Molecular Imaging, 2024, v. 51, n. 7, p. 1926, doi. 10.1007/s00259-024-06621-0
By:
- Chen, Zhenying;
- Yang, Apeng;
- Chen, Aihong;
- Dong, Jinfeng;
- Lin, Junfang;
- Huang, Chao;
- Zhang, Jiaying;
- Liu, Huimin;
- Zeng, Zhiyong;
- Miao, Weibing
Publication type:
Article

Found: 8

NCX1 disturbs calcium homeostasis and promotes RANKL-induced osteoclast differentiation by regulating JNK/c-Fos/NFATc1 signaling pathway in multiple myeloma.

CXCR4-Directed PET/CT with [<sup>68</sup>Ga]Pentixafor in Central Nervous System Lymphoma: A Comparison with [<sup>18</sup>F]FDG PET/CT.

Single cell RNA-seq data and bulk gene profiles reveal a novel signature of disease progression in multiple myeloma.

Allo-HSCT recipients with invasive fungal disease and ongoing immunosuppression have a high risk for developing tuberculosis.

Akt2 mediates glucocorticoid resistance in lymphoid malignancies through FoxO3a/Bim axis and serves as a direct target for resistance reversal.

SSBP1 is a novel prognostic marker and promotes disease progression via p38MAPK signaling pathway in multiple myeloma.

Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study.

[<sup>68</sup>Ga]Pentixafor PET/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [<sup>18</sup>F]FDG PET/CT.